Sekhmet Pharmaventures

Sekhmet Pharmaventures

"Your trusted business partner"

Optimus

BULK DRUGS
A D P L
Anjan Drug Private Limited

SEKHMET PHARMAVENTURES

SEKHMET GROUP

2020

Sekhmet Pharmaventures was formed.

2020

Anjan Bulk Drugs Pvt. Ltd. was acquired - world renowned manufacturer of Intermediates and APIs

2022

Optimus Group was acquired
- a global player in the manufacture of Intermediates, APIs and Formulations

Sekhmet Pharmaventures

Optimus

Founded in 2004
3 API & 1 FDF
Facilitates

BULK DRUGS A D P L Anjan Drug Private Limited

Founded in 1990,
2 API Facilities

SEKHMET PHARMAVENTURES AT GLANCE

Revenue: USD 135+ Mn

One of the fastest growing CDMO/API Manufacturer

Facilities: 6 Mfg. Plants (5 APIs, 1 FDF)

API Plants with Capacities over 1300 KL+

Products: 70+ APIs, 30+ FDFs

Strong portfolio of API products with 50+ USDMFs.

Global Accreditations: USFDA, EU, ANVISA, WHOGMP, KFDA, TGA

Globally recognized and accredited mfg. sites to cater global markets.

Legacy: 20+ Years of Experience in API Manufacturing

Optimus & Anjan has rich experience and Global recognition.

Key Customers: Sanofi, Abbott, Pfizer, Sumitomo, Teva & more.

Trusted supplier to Innovators and Big Pharma.

OUR EXPERTISE

CDMO & CMO

Strong R&D to develop and manufacture products for our local and international partners

ACTIVE PHARMACEUTICAL INGREDIENTS

Fastest growing API player with 70+ products across therapeutic segments

ADVANCED INTERMEDIATES

32+ years of experience in producing Advanced Drug Intermediates for the global pharmaceutical industry

FORMULATIONS

Diverse portfolio & products registered in global markets including the US, Europe, Australia, Russia etc.

CORE COMPETENCIES

Intermediates to APIs to Finished Formulations Best Quality -
20% of our workforce designated to compliance

Focus on Research & Innovation to Develop Complex Molecules.
12% of our annual revenue spent on Research and Development



Technology Transfer from laboratory to Industry scale in **Minimum** lead time

MANAGEMENT TEAM – SEKHMET

Santosh Mahil
Managing Director and Chief Executive Officer
30+ Years

Mukesh Agarwal
Chief Financial Officer
21+ Years

Dr Jayprakash P
Head – R&D
23+ Years

Sumit Kumar
Chief Commercial Officer
24+ Years

Harsha Vardhan
Head – Quality
22+ Years

Durga Prasad
Head – Operations
30+ Years

Jitendra Jalan
Chief Human Resource Officer
25+ Years

KEY OFFERINGS - *API & ADVANCED INTERMEDIATES*

API

- **Comprehensive API** Solutions from process development to commercial manufacturing, with a dedicated **R&D center** and **5** strategically located **manufacturing** facilities for efficient scale-up and global supply
- Proven track record of developing over **100+** APIs developed involving various types of **complex chemistries and technologies**

RSM & Advanced Intermediates

- Our intermediates are tailored for **CDMO services**, supporting clinical phase development until commercial scale manufacturing
- **Developed over 55+ Advanced intermediates** across various therapeutic categories such as oncology, anti-coagulants, anti-inflammatory among others

Regulatory & Quality Compliance

- **Regulatory Expertise:** Sekhmet Pharma supports clients with over 100+ regulatory filings globally, including **50+ USDMFs** and **14+ CEPs**
- Partnered with Innovators for **NDA** Programs **–** including Regulatory CMC Support
- **Advanced Risk Assessment:** Expertise in mutagenic impurity classification and **N-nitrosamine** risk assessments ensures safety compliance with regulatory guidelines

KEY OFFERINGS - *FORMULATIONS*

"Our offerings include tablets, capsules, pellets, creams, and lotions across product categories"

Tablet Dosage Forms

- **Immediate release** ; Extended release by matrix, reservoir, osmotic and bilayer
- **Delayed Release** by enteric coating by MUPS (multi unit particulate System), Micro tablets by multi tip tooling technique
- Tablets **for Oral Suspension**; Dispersible tablets; Chewable tablets ; Effervescent tablets

Powders, Pellets & Capsules

- **Wurster coating,** Extrusion and Spheronization
- Hard gelatin capsules filled with powder, pellets, mini tablets and combination of tablets & Pellets
- Dual drug delivery ; Multi unit particulate system
- Powder For Oral Suspension **(PFOS)**

Semisolids

- **Ointments**, Creams & Lotions
- Controlled/**Extended-Release** Gel

STATE-OF-THE-ART R&D CENTER

"Our R&D collaborates with **Global Pharmaceutical ,** Specialty Chemical Companies and **Innovators** to develop innovative, safe, and cost-effective processes for NCEs, RSMs, Advanced Intermediates and APIs"

R&D Center
Hyderabad, India

Salient Features

- 45000 sq. ft. dedicated to R&D infrastructure
- Well-qualified team of over **150+** experienced scientists working on challenging product development
- Adherence to strict regulatory guidelines and compliance with **GLP** and other relevant quality standards
- Advanced Infrastructure such as Kilo Lab, Oncology Facility,

CAPABILITIES – *OVERVIEW*

Synthesis

- Expertise in **complex** and innovative chemistries
- **Green** Chemistry
- Average time **4 to 5 Stage** Development is ~ **10 to 12 months** *(*par with Benchmark)*

Analytical Chemistry

- **24*7** Analytical support
- LC-MS, GCMS, XRD capabilities
- ✓ Method Development and validation for **nitrosamine** impurities
- ✓ **21 CFR** Compliance

Technology Transfer (TT) & Scale-Up

- Fast Technology transfer from **Lab** Scale to **Kilo** Scale followed by **Piloting**
- Dedicated **5-member** team for Technology Transfer
- Ensuring Process **Safety** & Quality **Consistency**

Formulation Development

- Topicals, Tablets, Capsules, Liquid Orals
- **Extended-release** dosage form available
- Stability Studies , Method Transfers
- **Method validation** support for NDA/ANDA

Value-Added Services

- **100% Regulatory** Support from product development to commercialization
- **Robust IP** Management Support

End-to-End Project Management

- Risk-Based **Stage Gate Process** implemented for Product Development
- **17** Project Squads for New Product Development and Cost Improvement
- **PMO – 3** Project Managers **+ 1** Program Manager

Sekhmet Pharmaventures

* Time taken from initiation to tech transfer as per benchmarking study

Optimus

BULK DRUGS A D P L Anjan Drug Private Limited

CAPABILITIES – R&D – *ANALYTICAL*

LCMS

XRD

✓ State-of-the-Art Analytical Facility

- **10,000+ sq. ft.** infrastructure with ultra-modern equipment
- Experienced team of **80+ analysts** providing 24/7 support
- ✓ **GLP-compliant** facility with a dedicated team of scientists for R&D needs

✓ Comprehensive Method Development & Validation

- Method **development** and **validation** aligned with global standards (**ICH** Q2(R1), Brazil, China, etc.)
- Transfer of analytical methods to QC at respective sites

✓ Chromatography & Specialized Testing

- Systems operating on Empower 3 with 21 CFR compliance.
- Expertise in detecting **genotoxic** impurities, **nitrosamines**, and NDSRIs using **XRD**, **HPLC**, **LC-MS, GC-MS**
- Particle size analysis using Malvern PSD analyzers

✓ Stability & Impurities

- Stability studies for development batches
- **Mass** and **NMR** Expertise
- Identification of unknown impurities/solvents via advanced LC-MS and GC-MS

CAPABILITIES - MFG. NETWORK | API

Unit-1
Hyderabad

- ✓ API and Advanced Intermediates
- Total Capacity – **295 KL**
- # of Clean Rooms – **9** (ISO Class 8)
- Area – 18 Acres
- Reactor configuration suitability : **Potent Molecules**
- ✓ Accreditation**:** USFDA, EUGMP, WHO-GMP, KFDA

Unit-2
Vishakapatnam

- ✓ API and Advanced Intermediates
- Total Capacity – **240 KL**
- # of Clean Rooms – **1** (ISO Class 8)
- Area – 10 Acres
- Reactor configuration suitability: **High Volume Products**

Unit-3
Hyderabad

- ✓ API and Advanced Intermediates
- Total Capacity – **380 KL**
- # of Clean Rooms – **6** (ISO Class 8)
- Area – 20 Acres
- Reactor configuration suitability: **Multi-Product**
- ✓ Accreditation**:** EUGMP, WHO-GMP, KFDA

Unit-5
Chennai

- ✓ API and Advanced Intermediates
- Total Capacity – **65 KL**
- # of Clean Rooms - **5**
- Area – 2 Acres
- Reactor configuration suitability: **API Purification**
- ✓ Accreditation**:** USFDA, EDQM, TGA, WHO-GMP, AFM

Unit-6
Chennai

- ✓ Advanced Intermediates
- Total Capacity – **300 KL**
- # of Clean Rooms - 1
- Area – 12 Acres
- Reactor configuration suitability : **High Volume Products**
- ✓ Accreditation**:** USFDA, EDQM, WHO-GMP, AFM

CAPABILITIES - MFG. NETWORK | FDF

Manufacturing Infrastructure Overview

~2 Billion/Year Capacity Tablets & Capsules

Annual Capacity



Area	No of line/Suites
• Granulation	4 Suites
• Compression	2 Suites [Legacy /Fette]
• Coating	3 Suites
• Encapsulation	1 Suite
• Blister packaging	2 Lines (BQS / B-Max)
• Bottle packaging	2 Line (Parle / Pharma pack)
• Creams manufacturing	2 Suites
• Creams/Lotion filling	2 Lines

Dosage Forms

OSD
- Tablets
- Capsules
- Pellets
- PFOS

SSD
- Creams
- Lotions



Analytical Testing Capabilities

- Equipment: **12 HPLC, 2 GC** with Empower 3FR4 software
- Server Integration: In-line with **21CFR** requirements
- **Microbial Testing**: Dedicated lab
- Chemical Lab: 5 dissolution apparatus with autosampler
- Advanced Tools**: XRD & LC-MS** for R&D investigations
- Expertise: Method transfer, validation, and stability studies

Stability Study Testing Capabilities

- 5 walk-in chambers **(25KL capacity**) with 21 CFR-compliant ICDAS software
- Additional Chambers: Photo stability and **2-8°C cooling chambers**
- Compliance: **GXP SOPs** for OOS, deviations, audit trails, and data backup

ESG - KEY HIGHLIGHTS AT SEKHMET

810 metric tons CO2 emission avoided through introduction of renewable energy

Achieved **30% water recycling** from total water withdrawal

All our sites have embraced the **3R waste hierarchy**

We achieved **7.7% share of women** among permanent employees

Invested over **Rs. 9+** Crores in CSR Projects

1307 metric tonnes of high calorific hazardous waste was **redirected to co-processing in cement industry** aligning our commitment to responsible waste disposal in FY 23

Achieved annual power savings of 66,44.00 kw , **cost savings of Rs. 5,94,656** through installation of BLDC motors in operational sites IN FY 23

Zero reportable fatalities and LTIFR during the FY23, FY24, showcases the commitment to safety, health and environment

Achieved Bronze medal in Ecovadis for our commitment to sustainable practices. Optimus 68 (Bronze), Anjan (67 (Bronze). Aspiring Gold Rating by 2027-28.

73% of total spent is made on significant suppliers in tier 1

Reported **zero cases of bribery and corruption**

Reduced Scope 1 & 2 emission from **51,761 tons** of CO2e in FY 23 to **36,489 tons** of CO2e in FY 24

Emission Intensity reduced from **11.12 KgCO2e in FY 23 to 6 KgCO2e in FY 24**



Click on report to access Sekhmet's Sustainability Report FY 23

Sekhmet Pharmaventures

Optimus

BULK DRUGS A D P L Anjan Drug Private Limited

Green & Sustainable Pharmaceutical Manufacturing Solutions

OUR GREEN MANUFACTURING EDGE

Water-Based Processes

Our Chemistry in water solutions to reduce Solvent dependency for safer, cleaner synthesis

Energy-Efficient Operations

Optimized reaction conditions to minimize energy footprint

Solvent-Free Technologies

Neat reactions to eliminate hazardous waste

Waste-Minimization

Closed-Loop recovery and recycling of solvents and reagents

Sustainable Raw Material Sourcing

Suppliers evaluated under Sustainable supply chain framework

Green Chemistry driving CDMO excellence

We integrate advanced green chemistry solutions — including **water-based** and **solvent-free processes**, and waste minimization — into our Contract Manufacturing operations. These innovations **enable effluent reduction**, process intensification, and **cost efficiency** while ensuring high-quality, scalable manufacturing for our clients

Key Water Based Chemistry Capabilities

- ESTER HYDROLYSIS
- DECARBOXYLATION
- ALKYLATION
- HOFFMAN REACTIONS
- SALTIFICATION
- DE-SALTING

OUR MARQUEE CLIENTS


Sekhmet
Pharmaventures
THANK YOU
Optimus
BULK DRUGS
A D P L
Anjan Drug
Private Limited